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ABSTRACT
Background: Previous retrospective surveys have shown that lipid manage-
ent goals are well achieved in patients with dyslipidemia at relatively low risk for
therosclerotic diseases. However, more than half of patients in high-risk groups have
ot achieved the management goals. Since these surveys, newer medications, includ-
ng rosuvastatin and ezetimibe, have emerged in clinical practice that may influence
ipid management.
Objective: To assess the current status of lipid management in high-risk
atients, we conducted a cross-sectional study between January and March 2010.
Methods: Eligible patients were those with dyslipidemia who were classified
into the primary prevention high-risk or secondary prevention groups according to
the Japan Atherosclerosis Society guideline for diagnosis and prevention of athero-
sclerotic cardiovascular diseases. Patient data were collected from 300 randomly
selected physicians at hospitals and clinics across Japan if patients had been receiving
the same statin with or without other lipid-lowering agents for3 months. The main
outcome was the percentage of patients who achieved the serum LDL-C goal accord-
ing to the guideline.
Results: Data were collected from 1720 patients. The LDL-C goal was achieved
in 56.5% of patients (447 of 791) in the primary prevention high-risk group and in
24.5% (103 of 420) in the secondary prevention group by statin monotherapy. For
patients who had not reached the LDL-C goal with statin therapy alone, 53.8% (113 of
210) in the primary prevention high-risk group and 63.8% (111 of 174) in the secondary
prevention group achieved their lipid management goal with the addition of ezetimibe.
Ezetimibe significantly lowered mean serum LDL-C levels by 17.9% to 34.6% when
added to various statins (P  0.001).
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Current Therapeutic ResearchConclusions: Although strong statins are available, lipid management in
igh-risk patients remains unsatisfactory. More aggressive treatment is needed for
hese patients. (Curr Ther Res Clin Exp. 2012;73:1–15) © 2012 Elsevier HS Journals,
nc. All rights reserved.
Key words: cross-sectional study, dyslipidemia, ezetimibe, hydroxymethyl-
lutaryl-CoA reductase inhibitors, lipid management.
INTRODUCTION
Atherosclerotic cardiovascular disease (such as coronary artery disease [CAD], cere-
brovascular disease, and peripheral arterial disease) is one of the major causes of
morbidity and mortality in developed and developing countries. Dyslipidemia is a
major risk factor of the disease. The results of previous epidemiologic and clinical
studies1–5 have shown that the incidence of cardiovascular events is associated with
erum lipid levels. Thus, treating patients with dyslipidemia and managing their
erum lipid levels are quite important to reducing the incidence of atherosclerotic
vents. Under these circumstances, recent guidelines recommend the treatment goals
f serum lipid levels according to the risk category in which an individual patient is
lassified.6–9 The Japan Atherosclerosis Society guideline for the diagnosis and
prevention of atherosclerotic cardiovascular diseases9 is one of these guidelines. In this
uideline, patients are classified into those without (primary prevention group) and
ith (secondary prevention group) a history of CAD. In the primary prevention
roup, patients are further classified into 3 groups of high, intermediate, and low risk
ccording to the number of risk factors in each patient. Lipid management goals are
et for each of these groups.
However, following these recommendations in clinical practice remains a chal-
enge. Although various treatments, including 3-hydroxy-3-methylglutaryl-coen-
yme A reductase inhibitors (statins), bile acid sequestrants, nicotinic acid, and fibric
cid derivatives (fibrates), have been used to date, many patients have not achieved the
ipid management goals. For example, the Japan Lipid Assessment Program (J-
AP)10 and the Lipid Management Program (LiMAP)11 surveyed the status of
lipid-lowering therapy and found poor lipid management in many patients. Both
surveys have shown that more than half of the patients in the primary prevention
high-risk and secondary prevention groups did not achieve the lipid management
goals, whereas 70% of patients in the primary prevention low- and intermediate-
risk groups did. These results indicate that serum lipid levels are not managed
appropriately in the high-risk groups despite the fact that more aggressive treatment
is needed in these groups.
After completion of the J-LAP and the LiMAP, rosuvastatin and ezetimibe were
approved in Japan. Rosuvastatin is a new statin that lowers serum LDL-C levels more
strongly than do other statins.12 Ezetimibe selectively inhibits the intestinal absorp-
tion of dietary and biliary cholesterol13 and then effectively further lowers serum
LDL-C levels when combined with other lipid-lowering agents.14 According to the
apanese lipid-lowering agent market research, rosuvastatin and ezetimibe are widely
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T. Teramoto et al.used at present, which suggests that the use of these agents may improve lipid
management in high-risk groups. Knowing the current status of lipid management
will provide important information when the guideline is reviewed and revised.
Accordingly, we conducted the Japan Lipid Guideline Achievement Program (JL-
GAP) to assess the status of lipid management in patients at high risk for athero-
sclerotic cardiovascular diseases. We investigated the impact of current therapies on
lipid management, not only statin monotherapy but also the use of statins combined
with other drugs.
PATIENTS AND METHODS
Study Design and Ethical Considerations
This cross-sectional study was conducted between January and March 2010 across
apan. We accessed a Japanese database of clinical physicians involved with the
reatment of dyslipidemia, and 1000 randomly selected physicians at university
ospitals, general hospitals, and primary care clinics were asked to respond to a survey
bout patients under their care. A third-party organization independent of the
L-GAP committee members sent the questionnaires to the physicians and collected
he data. No identifying information, such as the name or initials of the patient, was
ollected.
Patient Population
Eligible patients were those with an elevated serum LDL-C level who experienced
AD, defined as myocardial infarction and/or symptomatic angina pectoris (the
econdary prevention group; LDL-C 100 mg/dL [to convert to millimoles per liter,
ultiply by 0.0259]), or had 3 major risk factors other than LDL-C without
xperiencing CAD (the primary prevention high-risk group; LDL-C 120 mg/dL)
ccording to the Japan Atherosclerosis Society 2007 guideline.9 Major risk factors
ther than LDL-C included the following: aging (men45 years, women55 years),
ypertension, diabetes (including impaired glucose tolerance), smoking, family his-
ory of CAD, and low HDL-C levels (40 mg/dL [to convert to millimoles per liter,
ultiply by 0.0259]). Patients with diabetes, cerebral infarction, or arteriosclerosis
bliterans were classified into the primary prevention high-risk group irrespective of
he number of risk factors they had. Data were collected if patients had been receiving
he same statin therapy with or without other lipid-lowering agents for 3 months.
ata were not collected if patients had established familial hypercholesterolemia or
hanged the daily dose of the statin within 3 months before the survey. Each physician
ollected the data from 5 to 10 consecutive patients.
Patient eligibility was decided by the survey organization after reviewing the
uestionnaires that had been completed and submitted by each primary care physi-
ian. The survey organization then informed the authors of the eligibility or noneli-
ibility of each patient. Patient selection was initiated after the physician(s) at each
nstitution approved the key points of the questionnaire from the survey organization
nd clearly indicated their intention to participate in the survey. Patients were
nrolled in the sequence in which they came to the hospital. Each physician selected
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Current Therapeutic Research5 to 10 consecutive eligible patients, completed the survey form for each of those
patients, and sent the completed forms to the survey organization. Individual phy-
sicians were informed by e-mail when their participation in the review was com-
pleted. This e-mail was sent by the survey organization at the end of the specified
period or when the physician had enrolled 10 patients. If a patient did not meet
the criteria for enrollment, that patient was excluded from this consecutive survey
and the next patient was considered for enrollment. Since this was a retrospective
review, informed consent was not generally obtained from patients by the medical
institutions.
Data Collection
In this study, 2 kinds of questionnaires were prepared: 1 for patients who received
tatin therapy alone and 1 for patients who received combination therapy with statins
nd other lipid-lowering agents. The number of patients receiving monotherapy and
ombination therapy was set at a ratio of 3:1. At present, statin monotherapy accounts
or 90% of the treatment provided for hyperlipidemia in Japan.11 However, current
recommendations are for more rigorous reduction of LDL-C levels, which is not
readily achieved with statin monotherapy in many cases. We felt a need to assess the
effect on lipid management of statin therapy combined with other drugs; however, to
perform such an assessment, we needed a specific number of cases for review. That is
why, in the present survey, we asked the participating physicians to include a certain
number of patients who were receiving combined treatment as part of the 5 to 10
consecutive patients that each physician selected for the survey.
The following data were collected for both groups of patients: demographic
characteristics (sex, age, height, and weight), absence/presence of the risk factors of
CAD (history of CAD, history of cerebral infarction, history of arteriosclerosis
obliterans, family history of CAD, current smoking, diabetes, and hypertension), and
serum HDL-C level before treatment (40 or 40 mg/dL). We also retrospectively
nvestigated serum lipid levels (total cholesterol, HDL-C, triglyceride, and LDL-C)
efore and 3 months after the start of current therapy. Triglycerides were measured
n the fasting state in principle. Serum LDL-C levels were recorded in the question-
aire if their values were obtained from direct homogeneous assay. Otherwise, serum
DL-C levels were calculated using the following Friedewald formula15: LDL-C 
Total Cholesterol – HDL-C – (Triglyceride/5).
In addition, the name and daily dose of the statin and the starting date of its use
were recorded for patients who received statin monotherapy. For patients who
received combination therapy, the names and daily doses of the statins and other
lipid-lowering agents and the starting date of the combination therapy were recorded.
After data collection, the number and percentage of patients who achieved the
LDL-C goal were analyzed. The LDL-C goal was defined as 120 mg/dL for the
primary prevention high-risk group and as100 mg/dL for the secondary prevention
group. These management goals were determined according to the recommendation
of the Japan Atherosclerosis Society guideline.9 The main outcome was the percentage
of patients who achieved the LDL-C goal.
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T. Teramoto et al.Statistical Considerations
Continuous variables are expressed as mean (SD). Categorical variables are ex-
ressed as frequencies and percentages. In patients who received statin therapy
ombined with ezetimibe, mean serum lipid levels were compared before and after
ombination therapy. The significance of pairwise comparison was determined using
he t test. A P  0.05 (2-sided) was considered statistically significant without
djustments for multiplicity. All the data were analyzed using a software program
SPSS; SPSS Inc., Chicago, Illinois).
Role of the Funding Source
This is an investigator-initiated study. The principal investigators designed the
tudy, and a third-party research organization (Athena Corp, Inc., Tokyo, Japan)
ollected the data. The principal investigators had full access to all the data and had
nal responsibility for the decision to submit for publication. We pooled the research
unds of the JL-GAP Committee to conduct this survey. No funding was obtained
rom private industry.
RESULTS
Study Patients
To recruit physicians for participation in this survey, we invited 1100 randomly
elected physicians from the database. From that group, 300 physicians agreed to
articipate and were sent questionnaires. We asked each participating physician to
rovide information about 5 to 10 patients. Under the survey plan, a 100% response
ate would require a mean of 7 questionnaire responses per physician, which would
rovide data from 2100 patients. We actually received 1720 responses (data from
720 patients), for a questionnaire return rate of 82%.
The percentage of patients in each geographic area well reflected the regional
istribution of the adult population in Japan (Figure 1). In the primary prevention
igh-risk group, data on 299 and 776 patients were collected from university and
eneral hospitals and primary care clinics, respectively. In the secondary prevention
roup, data on 395 and 250 patients were collected from university and general
ospitals and primary care clinics, respectively.
Table I shows the demographic and baseline characteristics of the patients. A total
f 1211 patients received statin monotherapy and 509 received statin therapy com-
ined with other lipid-lowering agents; their mean (SD) ages were 68.2 (10.6) and
4.7 (9.9) years, respectively. In the monotherapy and combination therapy groups,
80% of patients had hypertension and 50% had diabetes.
Table II shows the number of patients treated with each lipid-lowering agent. In
he monotherapy group, the more commonly used statins were atorvastatin, rosuv-
statin, and pravastatin. In the combination therapy group, the most frequently used
rug combined with statin was ezetimibe. Mean daily doses of statins are also
ummarized in Table II.
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Current Therapeutic ResearchStatus of Lipid Management by Statin Monotherapy
Figure 2 shows the percentages of patients who achieved the LDL-C goal in the
rimary prevention high-risk group. In total, 56.5% of patients (447 of 791) achieved
he target level of LDL-C. The achieving-goal rates ranged from 39.7% to 68.6%
ccording to the statin used, and 60% of patients who received simvastatin,
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Figure 1. Geographic distribution of the study patients across Japan compared with that
of the general adult population.
Table I. Demographic and baseline characteristics of the patients.
Characteristic
Statin Monotherapy
(n  1211)
Combination Therapy
(n  509)
Age, mean (SD), y 68.2 (10.6) 64.7 (9.9)
Sex, M/F, No. (%) 571 (47.2)/640 (52.8) 276 (54.2)/233 (45.8)
BMI, mean (SD) 24.7 (10.9) 25.2 (3.5)
Complications, No. (%)
Diabetes 660 (54.5) 259 (50.9)
Hypertension 1003 (82.8) 454 (89.2)
Smoking 456 (37.7) 268 (52.7)
Low HDL-C 229 (18.9) 116 (22.8)
Family history of CAD 240 (19.8) 148 (29.1)
ASO 136 (11.2) 57 (11.2)
Stroke 290 (23.9) 89 (17.5)
CAD 420 (34.7) 225 (44.2)
ASO  arteriosclerosis obliterans; BMI  body mass index (calculated as weight in kilograms divided by
eight in meters squared); CAD  coronary artery disease.
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T. Teramoto et al.pitavastatin, or rosuvastatin achieved the goal. Figure 3 shows the distribution of
serum LDL-C levels in the primary prevention high-risk group. Serum LDL-C levels
ranged from 120 to 150 mg/dL in one third of patients, which indicated that they
could reach the goal if their serum LDL-C levels further decreased by 10 to 30 mg/dL.
Figure 4 shows the percentages of patients who achieved the LDL-C goal in the
secondary prevention group. The achieving-goal rate was only 24.5% (103 of 420) in
total and ranged from 14.5% to 33.0% according to the statin used. The highest
percentage (33.0%) was obtained in the subgroup of patients who received rosuvas-
tatin. Figure 5 shows the distribution of serum LDL-C levels in the secondary
prevention group. Serum LDL-C levels ranged from 100 to 130 mg/dL in more than
half of the patients, which indicated that they could reach the goal if their serum
LDL-C levels further decreased by 10 to 30 mg/dL. Although the data are not shown,
the rates of achieving the LDL-C goal were similar between patients at university and
general hospitals.
Effects of Combination Therapy
Table III shows the achieving-goal rates after combination therapy was started in
Table II. Number of patients treated with each lipid-lowering agent.
Therapy
Primary Prevention
High-Risk Group
Secondary Prevention
Group Total
tatin monotherapy,
No. (%) [dose,
mean (SD), mg/dL]
Pravastatin 170 (21.5) [8.5 (2.3)] 83 (19.8) [9.0 (2.0)] 253
Simvastatin 30 (3.8) [5.8 (1.9)] 46 (11.0) [5.5 (1.6)] 76
Fluvastatin 58 (7.3) [23.4 (6.9)] 21 (5.0) [22.0 (6.8)] 79
Atorvastatin 236 (29.8) [8.3 (2.4)] 107 (25.5) [9.0 (2.1)] 343
Pitavastatin 125 (15.8) [1.6 (0.5)] 57 (13.6) [1.8 (0.4)] 182
Rosuvastatin 172 (21.7) [3.0 (1.0)] 106 (25.2) [3.1 (1.1)] 278
Subtotal 791 420 1211
ombination therapy,
No. (%)
Ezetimibe 210 (73.9) 174 (77.3) 384
Eicosapentaenoic
acid
38 (13.4) 23 (10.2) 61
Bezafibrate 22 (7.7) 14 (6.2) 36
Fenofibrate 8 (2.8) 5 (2.2) 13
Colestimide 1 (0.4) 6 (2.7) 7
Probucol 4 (1.4) 2 (0.9) 6
Nicotinic acid 1 (0.4) 1 (0.4) 2
Subtotal 284 225 509atients who had not reached the LDL-C goal with statin therapy alone. The addition
7
Current Therapeutic Researchof ezetimibe provided relatively high rates of achieving the goal in 53.8% of patients
(113 of 210) in the primary prevention high-risk group and in 63.8% (111 of 174)
in the secondary prevention group. In contrast, the addition of other lipid-lowering
agents provided achieving-goal rates of 24.3% (18 of 74) and 15.7% (8 of 51),
respectively. The achieving-goal rates in the statin-ezetimibe combination therapy
varied depending on the statin used, ranging from 43.1% to 73.3% in the primary
prevention high-risk group (Figure 6) and from 56.1% to 79.2% in the secondary
prevention group (Figure 7).
Table IV shows the changes in serum lipid levels between pretreatment and post-
treatment with ezetimibe in patients who had not reached the LDL-C goal with statin
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Figure 2. Percentages of patients who achieved target levels of LDL-C in the primary
prevention high-risk group stratified according to the statin administered.
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T. Teramoto et al.therapy alone. Treatment including ezetimibe significantly lowered mean serum LDL-C
levels by approximately 30% to 40% in the primary prevention high-risk and secondary
prevention groups (P  0.001). Other serum lipid levels also improved in both groups.
he effects of ezetimibe on LDL-C reduction did not differ greatly regardless of the statin
ombined (Table V). Ezetimibe therapy significantly decreased mean serum LDL-C levels
y 17.9% to 34.6% when added to various statins (all, P  0.001). Ezetimibe therapy
lso improved mean serum levels of total cholesterol, triglyceride, and HDL-C.
DISCUSSION
These study results show that lipid management remains unsatisfactory in high-risk
patients with dyslipidemia. The percentage of patients who achieved the LDL-C goal
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Current Therapeutic Researchwas 56.5% in the primary prevention high-risk group and 24.5% in the secondary
prevention group. These percentages are similar to those reported in the J-LAP10 and
LiMAP11 studies, which suggests that even the emergence of rosuvastatin, the
strongest statin so far, has not improved lipid management markedly. More aggres-
sive treatment is needed in these groups.
These results also suggest that monotherapy with a statin may be limited to
accomplish the lipid management goal in these patients. Statins lower serum cho-
Table III. Achieving-goal rates after combination therapy.
Therapy
Primary Prevention High-Risk
Group Secondary Prevention Group
Total
No. of
Patients
Patients
Achieving
Goal, No.*
Achieving-
Goal
Rate, %
Total
No. of
Patients
Patients
Achieving
Goal, No.†
Achieving-
Goal
Rate, %
Ezetimibe 210 113 53.8 174 111 63.8
Eicosapentaenoic
acid
38 10 26.3 23 4 17.4
Bezafibrate 22 1 4.5 14 2 14.3
Fenofibrate 8 2 25.0 5 0 0
Colestimide 1 0 0 6 2 33.3
Probucol 4 4 100 2 0 0
Nicotinic acid 1 1 100 1 0 0
Total 284 131 46.1 225 119 52.9
*Goal is an LDL-C level 120 mg/dL (to convert to millimoles per liter, multiply by 0.0259).
†Goal is an LDL-C level 100 mg/dL.
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Figure 6. Percentages of patients in the primary prevention high-risk group achieving the
LDL-C goal after the addition of ezetimibe who could not achieve target levels
with statin therapy alone.
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T. Teramoto et al.lesterol levels mainly by inhibiting cholesterol synthesis in the liver. However,
inhibition of cholesterol synthesis may increase the intestinal absorption of cholesterol
to compensate for the decreased amount of cholesterol, and the amount of cholesterol
absorption may become greater when statins strongly inhibit cholesterol synthe-
sis.16,17 Thus, achieving-goal rates may not improve solely by increasing the dose of
tatin or by switching the statin to a stronger one.
In contrast, the addition of ezetimibe to statin therapy provided relatively high
chieving-goal rates. In patients who could not reach the LDL-C goal with statin therapy
lone, 53.8% and 63.8% of patients in the primary prevention high-risk and secondary
revention groups, respectively, achieved the goal with the use of ezetimibe. These rates
ere generally higher than those obtained by other lipid-lowering agents. These results
lso show that many patients can achieve the LDL-C goal if their serum LDL-C levels
urther decrease by 10 to 30 mg/dL. Thus, lipid management may be improved by adding
zetimibe to statin therapy. Although the achieving-goal rates in the statin-ezetimibe
ombination varied depending on the statin administered, this variation was provably
wing to the relatively small sample size in each subgroup. In fact, these results show that
he addition of ezetimibe lowered mean serum LDL-C levels by approximately 30%
rrespective of the statin used. Ezetimibe also improved mean serum levels of total
holesterol, triglyceride, and HDL-C, which suggests effectiveness on overall lipid man-
gement. In long-term statin administration, reduced cholesterol synthesis has been
ssociated with a compensation mechanism that accelerates cholesterol absorption by the
iver.17 Because ezetimibe acts to reduce cholesterol absorption, combination therapy with
ezetimibe may contribute to the reduction in LDL-C levels in such patients. An overseas
study in patients with primary hypercholesterolemia showed that combined treatment
with ezetimibe produced a significantly greater decrease in LDL-C than was obtained from
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goal after the addition of ezetimibe who could not achieve target levels with
statin therapy alone. The results from the fluvastatin group are not shown
because only 1 patient received fluvastatin.increasing the initial dose of atorvastatin.18 Especially in Japan, it is reported that
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Current Therapeutic Researchcholesterol intake has been increasing year by year.19 Therefore, it has been hoped that
zetimibe combined with other lipid-lowering agents will prove to be effective therapy in
apanese patients. In that context, since 2008, results have been published from a variety
f large-scale studies of concomitant treatment with statins and ezetimibe in patients with
therosclerotic disease: the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances
therosclerosis Regression (ENHANCE),20 Simvastatin and Ezetimibe in Aortic Stenosis
(SEAS),21 and Arterial Biology for the Investigation of the Treatment Effects of Reducing
holesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER
-HALTS)22 studies. The ENHANCE and ARBITER 6-HALTS studies evaluated
changes in intima-media thickness, and the SEAS study had as its primary outcome aortic
valve replacement and death from cardiovascular causes. None of these studies showed
arteriosclerosis regression or inhibition of related events. However, in 2011, the results of
the Study of Heart and Renal Protection (SHARP) in patients with chronic kidney disease
showed a reduction in atherosclerotic events associated with the combined use of
ezetimibe and simvastatin.23 No relevant large-scale clinical studies of ezetimibe have
Table IV. Changes in serum lipid levels between pretreatment and posttreatment with
ezetimibe in patients who had not reached the LDL-C goal with statin therapy alone.
Group
No. of
Patients
Serum Lipid Concentration,
Mean (SD), mg/dL
% Change,
Mean (SD) PBefore After
Total patients
TC 320 257.3 (28.0) 197.7 (28.9) –22.9 (9.5) .001
LDL-C 384 165.8 (27.6) 113.2 (27.5) 31.4 (12.9) .001
TG 382 203.1 (78.4) 168.4 (102.9) 12.8 (33.5) .001
HDL-C 381 49.3 (12.4) 51.7 (12.6) 6.1 (13.5) .001
Primary prevention high-
risk group
TC 154 262.1 (28.2) 212.6 (31.0) 18.7 (9.8) .001
LDL-C 210 171.2 (30.7) 123.8 (30.7) 27.3 (13.9) .001
TG 208 187.1 (84.2) 168.8 (134.5) 5.8 (40.3) .001
HDL-C 207 49.9 (14.1) 53.3 (14.6) 8.2 (15.1) .001
Secondary prevention
group
TC 166 252.9 (27.1) 183.7 (17.8) 26.9 (7.3) .001
LDL-C 174 159.3 (21.6) 100.2 (15.2) 36.3 (10.0) .001
TG 174 222.2 (66.4) 168.0 (41.0) 21.1 (20.1) .001
HDL-C 174 48.6 (10.0) 49.9 (9.4) 3.5 (10.8) .01
TC  total cholesterol; TG  triglyceride.been published in Japan to date, and, to our knowledge, none have yet been undertaken
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T. Teramoto et al.in the rest of Asia. We look forward to the results of future large-scale clinical studies that
have cardiovascular events as their primary end point.
Some limitations of this study should be mentioned. First, this is a cross-sectional
study, which is not an appropriate design to evaluate the treatment effects on any
outcome. Although we reported the changes in serum lipid levels between pretreat-
ment and posttreatment with ezetimibe, the effects of adding ezetimibe to statin
therapy should be confirmed by a prospective longitudinal study or a randomized
controlled trial. Second, patients who could not tolerate the same statin for 3
months were excluded. This exclusion may lead to overestimation of the percentage
of patients who achieved the LDL-C goal because serum lipids may be poorly
managed in these patients. Third, we used serum LDL-C levels obtained from direct
homogeneous assay or calculated using the Friedewald formula, which may lead to
imprecise reporting of the LDL-C management.
CONCLUSIONS
Although strong statins are available, lipid management in patients in the primary
prevention high-risk and secondary prevention groups remains unsatisfactory. Per-
centages of patients who achieved the LDL-C goal are similar to those reported in the
previous study, which indicates that more aggressive treatment is needed for these
patients. Lipid management may be improved by adding ezetimibe to statin therapy.
Further study is warranted to confirm the effectiveness of ezetimibe.
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P  0.001 for all.article.
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